A Selective TRPC3 Inhibitor Pyr3 Attenuates Myocardial Ischemia/Reperfusion Injury in Mice
- PMID: 33428139
- DOI: 10.1007/s11596-020-2293-y
A Selective TRPC3 Inhibitor Pyr3 Attenuates Myocardial Ischemia/Reperfusion Injury in Mice
Abstract
An emerging body of evidence indicates that transient receptor potential TRP channels act as important mediators for a wide variety of physiological functions and are potential targets for drug discovery. Our previous study has identified transient receptor potential channel 3 (TRPC3) and TRPC6 as cation channels through which most of the damaging calcium enters, aggravates pathological changes in vivo and increases ischemia/reperfusion (I/R) injury in mice. This study aimed to verify the effects of TRPC3 inhibitor Pyr3 on myocardial I/R injury in mice. C57BL/6J wild-type male mice (8 to 12 weeks old) were anesthetized with 3.3% chloral hydrate. A murine I (30 min)/R (24 h) injury model was established by temporary occlusion of the left anterior descending (LAD) coronary artery. Pyr3 was administered at concentrations of 0, 2.5, 5, or 10 mg/kg via the right jugular vein 5 min before reperfusion. We observed that the selective TRPC3 inhibitor, 10 mg/kg Pyr3, significantly decreased the infarct size of left ventricle, and reduced the myocardial cell apoptosis rate and inflammatory response in mice. In a conclusion, TRPC3 can function as a candidate target for I/R injury prevention, and Pyr3 may directly bind to TRPC3 channel protein, inhibit TRPC3 channel activity, and improve TRPC3-related myocardial I/R injury. Pyr3 may be used for clarification of TRPC3 functions and for treatments of TRPC3-mediated diseases.
Keywords: Pyr3; TRPC3; apoptosis; ischemia/reperfusion injury.
Similar articles
-
Overexpression of TRPC3 increases apoptosis but not necrosis in response to ischemia-reperfusion in adult mouse cardiomyocytes.Am J Physiol Cell Physiol. 2008 Mar;294(3):C833-41. doi: 10.1152/ajpcell.00313.2007. Epub 2008 Jan 9. Am J Physiol Cell Physiol. 2008. PMID: 18184877 Free PMC article.
-
Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound.Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5400-5. doi: 10.1073/pnas.0808793106. Epub 2009 Mar 16. Proc Natl Acad Sci U S A. 2009. PMID: 19289841 Free PMC article.
-
[Pharmacological properties of novel TRPC channel inhibitors].Yakugaku Zasshi. 2010 Mar;130(3):303-11. doi: 10.1248/yakushi.130.303. Yakugaku Zasshi. 2010. PMID: 20190514 Review. Japanese.
-
Major contribution of the 3/6/7 class of TRPC channels to myocardial ischemia/reperfusion and cellular hypoxia/reoxygenation injuries.Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4582-E4591. doi: 10.1073/pnas.1621384114. Epub 2017 May 19. Proc Natl Acad Sci U S A. 2017. PMID: 28526717 Free PMC article.
-
Pharmacological modulation of diacylglycerol-sensitive TRPC3/6/7 channels.Curr Pharm Biotechnol. 2011 Jan 1;12(1):35-41. doi: 10.2174/138920111793937943. Curr Pharm Biotechnol. 2011. PMID: 20932261 Free PMC article. Review.
Cited by
-
Post-injury Inhibition of Endothelin-1 Dependent Renal Vasoregulation Mitigates Rhabdomyolysis-Induced Acute Kidney Injury.Function (Oxf). 2023 May 4;4(4):zqad022. doi: 10.1093/function/zqad022. eCollection 2023. Function (Oxf). 2023. PMID: 37342410 Free PMC article.
-
Duloxetine HCl Alleviates Asthma Symptoms by Regulating PI3K/AKT/mTOR and Nrf2/HO-1 Signaling Pathways.Inflammation. 2023 Dec;46(6):2449-2469. doi: 10.1007/s10753-023-01892-5. Epub 2023 Aug 30. Inflammation. 2023. PMID: 37644164
-
VDAC1, as a downstream molecule of MLKL, participates in OGD/R-induced necroptosis by inducing mitochondrial damage.Heliyon. 2023 Dec 11;10(1):e23426. doi: 10.1016/j.heliyon.2023.e23426. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38173512 Free PMC article.
-
Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma.Front Pharmacol. 2024 May 10;15:1345070. doi: 10.3389/fphar.2024.1345070. eCollection 2024. Front Pharmacol. 2024. PMID: 38799165 Free PMC article.
-
TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases.Signal Transduct Target Ther. 2023 Jul 5;8(1):261. doi: 10.1038/s41392-023-01464-x. Signal Transduct Target Ther. 2023. PMID: 37402746 Free PMC article. Review.
References
-
- Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev, 2008,88(2):581–609 - DOI
-
- Paddison PJ, Cleary M, Silva JM, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods, 2004,1(2): 163–167 - DOI
-
- Kiyonaka S, Kato K, Nishida M, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Nat Acad Sci USA, 2009,106(13): 5400–5405 - DOI
-
- Seo K, Rainer PP, Shalkey Hahn V, et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc Nat Acad Sci USA, 2014, 111(4):1551–1556 - DOI
-
- Kitajima N, Numaga-Tomita T, Watanable M, et al. TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling. Sci Rep, 2016, 6:37001 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources